MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2017 International Congress

    Levodopa induced dyskinesia in a case of progressive supranuclear palsy.

    T. Yamamoto, H. Kawasaki, T. Furuya, A. Miyake, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, K. Takahashi, N. Tamura, N. Araki (Saitama, Japan)

    Objective: We describe the mechanism of dyskinesia in patients with progressive supranuclear palsy (PSP). Background: Levodopa generally shows a poor effect to parkinsonism in patients…
  • 2017 International Congress

    Personal KinetiGraph (PKG) for Parkinson’s Disease: Experience at a Tertiary Care Center

    V. Sharma, A. Fowler, K. Lyons, R. Pahwa (Kansas City, KS, USA)

    Objective: To assess objective measurements by Personal KinetiGraph (PKG) in Parkinson’s disease (PD) patients and compare them to self-reported symptoms.   Background: Personal Kinetigraph (PKG)…
  • 2017 International Congress

    Knowledge of Levododopa-induced Dyskinesias among PD patients

    R. Doyle Maia, F. Cardoso, P. Caramelli (Vitória, Brazil)

    Objective: The aim of this study was to investigate the level of knowledge of LIDs in PD patients and their proxies in a tertiary hospital. …
  • 2017 International Congress

    Impact of levodopa-induced dyskinesias on Health-related Quality of Life. Results from the French COPARK study.

    S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Buenos Aires, Argentina)

    Objective: To assess the impact of LIDs on HRQoL in this large sample of unselected Parkinson’s Disease (PD) patients and to assess the factors related…
  • 2017 International Congress

    Protocol for upper-limb kinematic analysis in paediatric movement disorders and relative normality data

    L. Garavaglia, E. Pagliano, A. Lo Mauro, G. Baranello, A. Aliverti, S. Pittaccio (Lecco, Italy)

    Objective: The study proposes a specialised protocol to collect and analyse kinematic data from paediatric patients affected by Movement Disorders (MD). The aim is to…
  • 2017 International Congress

    Factors associated with occurrence of motor complications among Parkinson’s disease patients with levodopa treatment in Estonia

    L. Kadastik-Eerme, N. Taba, T. Asser, P. Taba (Tartu, Estonia)

    Objective: To identify the factors associated with the occurrence of motor complications among patients with Parkinson’s disease (PD) who receive levodopa treatment. Background:  Levodopa is the…
  • 2017 International Congress

    How efficient is subthalamic deep brain stimulation in reducing dyskinesia in Parkinson’s Disease?

    N. Kovacs, A. Juhász, I. Balás (Pecs, Hungary)

    Objective: The aim of this study was to determine whether the UDysRS can detect improvement in dyskinesia reliably after bilateral subthalamic nucleus DBS for PD.…
  • 2017 International Congress

    Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.

    M. Marano, M. Marano, L. di Biase, R. Arca, G. Cossu, E. Coletta, V. Di Lazzaro, A. Fasano, P. Marano (Rome, Italy)

    Objective: To describe the occurrence, diagnostic approach, clinical management and outcome of diphasic dyskinesias (Dyskinesias-Improvement-Dyskinesias, DID) in a large group of Parkinson’s Disaese (PD) patients…
  • 2017 International Congress

    Antiphospholipid syndrome presenting with craniocervical dystonia: A case study

    C. Dietiker, C. Clelland, S. Gupta, M. Richie, M. Shah, I. Bledsoe (San Francisco, CA, USA)

    Objective: Antiphospholipid Syndrome (APLS) is a hypercoagulable state characterized by arterial or venous thrombosis and/or pregnancy morbidity with laboratory evidence of antiphospholipid antibodies. Movement disorders…
  • 2017 International Congress

    Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

    K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

    Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 44
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley